Studies have shown that HLJDD reduced the production of inflammatory mediators by inhibiting MAPKs and NF-κB pathways and significantly improved the symptoms of atopic dermatitis in mice [34], and HLJDD alleviates the clinical symptoms of pneumonia by regulating the host's immune inflammatory response and oxidative stress [35]. The gene discussed is NFKB1; the disease is atopic eczema.